News By Tag Industry News News By Location Country(s) Industry News
| ![]() DelveInsight Released Top Line Analytical Reports on Blood Coagulation and Cancer marketsDelveInsight has highlighted current and future market of Anticoagulants and Programmed cell death 1 (PD-1) Inhibitors.
By: DelveInsight DelveInsight Report, “Anticoagulants- DelveInsight Report, “Programmed cell death 1 (PD-1) Inhibitors” analyzes the market of PD-1 and PD-L1 inhibitors, their pathways, MOAs, marketed molecules, detail profiling of Pipeline assets highlighting all the indications. DelveInsight Analysis predicts that PD-1 and PD-L1 inhibitors are among the upcoming and highly growing fields in biopharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. Future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. There are 2 marketed products of PD-1 and PD-L1 inhibitors. According to DelveInsight analysis, Merck's Keytruda and Bristol’s Opdivo believe to be major blockbusters in the market. For further information and Sample Pages, mail at info@delveInsight.com End
Page Updated Last on: Apr 07, 2015
|
|